Core Points - The company Gushengtang has been actively repurchasing its shares, with a total of 558,980 shares bought back since September 10, amounting to HKD 173 million [2] - The stock price has seen a decline of 14.27% during the repurchase period, with the latest closing price at HKD 28.540, down 2.33% on the day of the latest buyback [2] - Year-to-date, Gushengtang has conducted 57 repurchase transactions, totaling 854,440 shares and an expenditure of HKD 267 million [2] Repurchase Details - On October 30, 2025, Gushengtang repurchased 29,010 shares at a price range of HKD 28.460 to HKD 29.080, with a total repurchase amount of HKD 8.3254 million [2] - The highest repurchase price during the recent buyback was HKD 29.320 on October 28, while the lowest was HKD 28.460 on October 30 [3] - The company has consistently repurchased shares over the past 34 days, indicating a strong commitment to supporting its stock price [2][3]

Core Viewpoint - *ST Shengxun (003004.SZ) reported a revenue of 139 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 31.21%. However, the company recorded a net loss attributable to shareholders of 3.7952 million yuan, with a net profit of -4.8579 million yuan after excluding non-recurring gains and losses, resulting in a basic earnings per share of -0.0464 yuan [1]. Financial Performance - Revenue for the first three quarters of 2025 reached 139 million yuan, marking a 31.21% increase compared to the previous year [1]. - The net profit attributable to shareholders was -3.7952 million yuan [1]. - The net profit after excluding non-recurring gains and losses was -4.8579 million yuan [1]. - Basic earnings per share stood at -0.0464 yuan [1].

Group 1 - The company Beike-W (02423) announced a share buyback plan, committing to repurchase 1.1766 million shares for a total cost of 7 million USD [1]

纳武利尤单抗是一种针对程序性细胞死亡1(「PD-1」)受体的人源化单克隆抗体(IgG4亚型)，通过阻断 PD-1受体与其配体PD-L1及PD-L2的结合来增强T细胞的抗肿瘤反应，是广谱的抗肿瘤药物。自2014年 获批成为全球首个PD-1抑制剂以来，欧狄沃?已在全球数十个国家和地区获批多项适应症，涵盖多个瘤 种，且临床应用贯穿肿瘤治疗各个阶段，包括术前新辅助治疗、术后辅助治疗、晚期肿瘤的一綫和後綫 治疗等，用法包括单药、联合化疗以及与新的免疫检查点抑制剂联用等。 BA1104遵循生物类似药相关研究指南进行研发，其在中国开展的Ⅲ期临床试验为一项随机、双盲、多 中心试验，旨在比较BA1104与欧狄沃®分别联合化疗治疗晚期或转移性食管鳞癌患者的有效性、安全 性和免疫原性。根据《生物类似药相似性评价和适应症外推技术指导原则》，BA1104在完成Ⅲ期临床 试验後可申请同时获批欧狄沃?在中国获批的全部适应症。已完成的Ⅰ期临床试验结果显示：BA1104与 欧狄沃®在PK、安全性和免疫原性高度可比，达到了所有研究终点，相关研究结果已发表于国际期刊 《BioDrugs》。 格隆汇10月30日丨博安生物(06955.HK)宣布，公 ...

Core Viewpoint - The company, Baima Tea Industry (06980.HK), has announced its plan to implement full circulation of H-shares by converting 31,933,125 domestic shares held by 11 shareholders into H-shares, which represents approximately 37.57% of the total issued shares as of the announcement date [1] Group 1 - The board of directors has approved the submission of a filing application to the China Securities Regulatory Commission (CSRC) for the conversion of domestic shares into H-shares [1] - The conversion will be eligible for listing and trading on the main board of the Stock Exchange of Hong Kong after obtaining all necessary approvals and complying with applicable laws and regulations [1] - According to the company's articles of association, no further approval from shareholders is required for the conversion and listing [1]

格隆汇10月30日丨培力农本方(01498.HK)宣布，董子铭获委任为非执行董事，自2025年10月30日起生 效。 ...

Core Viewpoint - The recent announcement by Power Development Group regarding significant progress in the Makhado project under MCMining Limited marks a crucial step in the company's international strategic deployment [1][2] Group 1: Company Strategy - Power Development Group is focusing on overseas high-potential resource projects to enhance risk resilience and long-term competitiveness, leveraging its mature operational experience and profitability in China's coal mining and sales [1] - The acquisition of shares in MCMining, which has multiple coking and thermal coal projects in South Africa, aligns with Power Development's core business and expands its resource reserves [1] Group 2: Project Development - The Makhado project is identified as one of the most promising hard coking and thermal coal development projects located in the Soutpansberg coalfield of Limpopo Province, South Africa, with all engineering works progressing as planned [1] - The operational experience from China's coal industry is expected to support the Makhado project's efficiency and profitability through systematic capabilities in mine management, cost control, and safety production [1] Group 3: Market Expansion - As the Makhado project gradually commences production, Power Development Group aims to establish a foothold in the South African market and expand international capital channels and resource cooperation opportunities through MCMining's dual listing platforms in Australia and Johannesburg [2] - The steady advancement of the Makhado project signifies that the company's overseas layout is entering a critical stage before harvest [2]

Group 1 - The company Jitu Express (极兔速递-W, 01519) announced a share buyback plan, intending to repurchase 388,000 shares at a cost of HKD 3.8545 million [1]

Core Points - 康臣药业 has been actively repurchasing its shares, with a total of 28,000 shares bought back on October 30 at prices ranging from 14.960 to 15.080 HKD, amounting to 4.2053 million HKD [1] - The stock has seen a decline of 5.94% since the start of the recent repurchase program on October 14, during which the company has repurchased a total of 2.65 million shares for 40.4171 million HKD [1] - Year-to-date, 康臣药业 has conducted 30 repurchase transactions, totaling 7.845 million shares and 98.9482 million HKD in repurchase amounts [1] Repurchase Details - On October 30, 康臣药业 repurchased 28,000 shares at a maximum price of 15.080 HKD and a minimum price of 14.960 HKD, totaling 4.2053 million HKD [2] - The company has consistently repurchased shares over the past 12 days, with the most significant repurchase occurring on October 23, where 42,200 shares were bought back at an average price of 15.040 HKD [1][2] - The cumulative repurchase activity reflects a strategic effort to stabilize the stock price amid a downward trend, as evidenced by the stock's closing price of 15.050 HKD on October 30, down 2.46% for the day [1]

（万港元） 2025.10.30 178.30 3.300 3.220 585.72 2025.10.27 30.30 3.280 3.250 98.76 2025.10.17 37.50 3.180 3.070 116.72 2025.10.10 29.40 3.330 3.280 97.10 2025.10.08 27.70 3.490 3.480 96.57 2025.09.23 27.80 3.560 3.490 98.31 2025.09.04 28.50 3.470 3.440 98.59 2025.09.03 27.70 3.560 3.540 98.31 2025.07.25 30.30 3.280 3.220 98.36 2025.07.02 36.30 2.740 2.700 99.08 2025.06.19 30.70 2.600 2.580 79.79 2025.06.18 28.50 2.710 2.670 76.71 2025.06.13 28.50 2.730 2.700 77.34 2025.06.02 27.10 2.600 2.510 69.32 2025.05.15 17 ...